phase

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China... » read more

New it.com Domain Name Goes into Sunrise Phase on 2nd January 2023

London, UK, December 30, 2022 – (SEAPRWire) – UK Intis Telecom LTD announces the launch of the new top-level domain name zone (TLD) – it.com. This new domain name extension represents a new & intelligent solution to the ever-depleting availability of great, short, and easy-to-remember domain names in other zones. The domain name has been in Conditional... » read more

Mazda: Mid-Term Management Plan Update and Management Policy up to 2030

HIROSHIMA, Japan, Nov 22, 2022 – (JCN Newswire via SEAPRWire.com) – Mazda Motor Corporation today announces an update to its Mid-Term Management Plan and basic management policies up to 2030. Taking into account the significant changes that have occurred in the business environment including countries’ environmental regulatory trends, heightened geopolitical risks, and rapid development of... » read more

80-160 year building use rights in IKN to attract investors: Minister

JAKARTA, Oct 12, 2022 – (ACN Newswire via SEAPRWire.com) – The Ministry of Agrarian and Spatial Planning/National Land Agency (ATR/BPN) is offering building use rights (HGB) of up to 80 and extendable to 160 years to attract investors to the new capital (IKN) Nusantara. Balang Island Short Span Bridge in Penajam North Paser Regency, East... » read more

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

SYDNEY, AU, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside... » read more

Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June... » read more

Nakamoto Games Entering New Growth Phase

Play-to-earn disruptor to finalize private sale token distribution ahead of schedule Mahe, Seychelles, June 25, 2022 – (SEAPRWire) -Nakamoto Games ($NAKA), the token powering the industry’s fastest-growing play-to-earn gaming ecosystem, is entering a new growth phase with exciting prospects. On Monday, June 27th, 2022, Nakamoto Games will release the last $NAKA token allocation batch to private sale investors.... » read more

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

HONG KONG, Jun 15, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject... » read more

Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 – (ACN Newswire via SEAPRWire.com) – Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021. Highlights— The group’s turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million; — Sales coverage increased to around 10,500... » read more

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21... » read more

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. Avance... » read more

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

HANGZHOU, CHINA, Jan 12, 2022 – (ACN Newswire via SEAPRWire.com) – On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of the phase I clinical trial data of its mRNA COVID-19 vaccine (LVRNA009). Safety data on the phase I clinical trial was released by Director Chen... » read more

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

TOKYO, Dec 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer’s disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab... » read more

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 30 November 2021, SM03 (Suciraslimab) Phase III... » read more

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension

TOKYO, Nov 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer’s disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies. The... » read more

MC and Kinki Sharyo Sign Contract with Egyptian Government for Rolling Stock Deliveries for Phase 1 of Cairo Metro Line 4

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Corporation (MC) and The Kinki Sharyo Co., Ltd. (Kinki Sharyo) are pleased to announce that we have signed a contract with National Authority for Tunnels (NAT) to deliver 184 cars of rolling stock for Phase 1 of Cairo Metro Line 4(New CP 412). The... » read more

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

HONG KONG, Sep 17, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (HKEX 3681.HK, “SinoMab”) announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. (“Sinovent”) today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, “Everest”) to out-license the right to develop and commercialize SN1011 (referred as “XNW1011” by Sinovent),... » read more

Bit2Me Raises 5 Million Euros as Phase One of ICO Sells Out in Under 60 Seconds

MADRID, Sep 7, 2021 – (ACN Newswire via SEAPRWire.com) – Bit2Me has closed the first phase of its ICO (Initial Coin Offering) in just 59 seconds, raising a figure of 5 million euros. This is the most successful token issue ever launched in Spain. The second phase will start on September 13 and the third... » read more

Kintor Pharma Announces 2021 Interim Results

SUZHOU, CHINA, Aug 30, 2021 – (ACN Newswire via SEAPRWire.com) – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities... » read more

Apollomics, Inc. Doses First Patient in Phase I Clinical Trial of APL-102

Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced... » read more